Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5026
Bolt Biotherapeutics
BOLT
$6.65M
| $33 | ﹤0.01% |
6
| – | – |
2022 Q1
15 quarters
|
|
|
PDYNW
5027
DELISTED
Palladyne AI Corp Warrants
PDYNW
| $31 | ﹤0.01% |
500
| – | – |
2022 Q1
15 quarters
|
|
5028
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
$10.9B
| $30 | ﹤0.01% |
1
| – | – |
2024 Q3
5 quarters
|
|
|
TWFG
5029
TWFG Inc
TWFG
$317M
| $29 | ﹤0.01% |
+1
| New | +$27 |
2025 Q4
0 quarters
|
|
5030
Global Indemnity Group
GBLI
$356M
| $28 | ﹤0.01% |
1
-1
| -50% | -$29 |
2022 Q1
15 quarters
|
|
|
GENVR
5031
Gen Digital Inc Contingent Value Rights
GENVR
| $27 | ﹤0.01% |
6
-12,900
| -100% | -$66K |
2025 Q2
2 quarters
|
|
5032
State Street SPDR Portfolio Aggregate Bond ETF
SPAB
$9.78B
| $26 | ﹤0.01% |
1
| – | – |
2024 Q4
4 quarters
|
|
5033
Hooker Furnishings Corp
HOFT
$141M
| $23 | ﹤0.01% |
2
-2
| -50% | -$20 |
2022 Q3
13 quarters
|
|
5034
State Street SPDR Portfolio Long Term Corporate Bond ETF
SPLB
$1.15B
| $23 | ﹤0.01% |
1
| – | – |
2024 Q4
4 quarters
|
|
5035
Blink Charging
BLNK
$81.3M
| $20 | ﹤0.01% |
29
-106,827
| -100% | -$155K |
2020 Q2
22 quarters
|
|
5036
QuickLogic
QUIK
$217M
| $18 | ﹤0.01% |
3
| – | – |
2024 Q2
6 quarters
|
|
5037
Zai Lab
ZLAB
$2.73B
| $18 | ﹤0.01% |
1
-734
| -100% | -$17.2K |
2022 Q1
15 quarters
|
|
5038
Harvard Bioscience
HBIO
$38M
| $14 | ﹤0.01% |
+2
| New | +$12 |
2025 Q4
0 quarters
|
|
5039
Quince Therapeutics
QNCX
$29.7M
| – | – |
0
| – | – |
2025 Q2
2 quarters
|
|
5040
a.k.a. Brands
AKA
$119M
| $11 | ﹤0.01% |
1
| – | – |
2024 Q2
6 quarters
|
|
5041
DLH Holdings
DLHC
$58.7M
| $11 | ﹤0.01% |
2
| – | – |
2023 Q3
9 quarters
|
|
5042
Ultralife
ULBI
$108M
| $11 | ﹤0.01% |
2
-1,580
| -100% | -$9.75K |
2023 Q3
9 quarters
|
|
|
LANV.WS
5043
DELISTED
Lanvin Group Holdings Warrants
LANV.WS
| $10 | ﹤0.01% |
500
| – | – |
2022 Q4
12 quarters
|
|
|
XTKG
5044
DELISTED
X3 Holdings Co., Ltd. Class A Ordinary Shares
XTKG
| $9 | ﹤0.01% |
+1
| New | +$274 |
2023 Q4
8 quarters
|
|
5045
CervoMed
CRVO
$45.7M
| $8 | ﹤0.01% |
1
| – | – |
2024 Q2
6 quarters
|
|
5046
Star Holdings Shares of Beneficial Interest
STHO
$102M
| $8 | ﹤0.01% |
1
-1,754
| -100% | -$13.4K |
2023 Q1
11 quarters
|
|
5047
Verrica Pharmaceuticals
VRCA
$75.2M
| $8 | ﹤0.01% |
1
| – | – |
2023 Q1
11 quarters
|
|
|
KZR
5048
DELISTED
Kezar Life Sciences
KZR
| $6 | ﹤0.01% |
1
| – | – |
2024 Q4
4 quarters
|
|
|
TEI
5049
Templeton Emerging Markets Income Fund
TEI
$287M
| $6 | ﹤0.01% |
+1
| New | +$6 |
2025 Q4
0 quarters
|
|
5050
Prospect Capital
PSEC
$1.07B
| $5 | ﹤0.01% |
2
-22,398
| -100% | -$59.8K |
2025 Q3
1 quarter
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.